Profound Medical Corp. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-03. Between them they name 3 people, with 2 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Richard R. Fabian, President
On September 1, 2026, Profound Medical Corp. (the "Company" or "Profound Medical") announced that Richard R. Fabian has been appointed by the Board of Directors of the Company (the "Board") to serve as the President of the Company, effective as of the same date (the "Appointment Date").
Appointed: Matthew Sobczyk, Chief Financial Officer
On August 14, 2026, Profound Medical Corp. (the "Company" or "Profound Medical") announced that Matthew Sobczyk has been appointed by the Board of Directors of the Company (the "Board") to serve as the Interim Chief Financial Officer of the Company, effective as of the same date (the "Appointment Date").
Departing: Rashed Dewan, Chief Financial Officer
Separation Agreement and Contractor Services Agreement On August 14, 2026, Rashed Dewan resigned from his position as Chief Financial Officer of the Company, effective the same day (the "Separation Date").
Find people with the same kind of experience as the President at Profound Medical Corp., with the record behind each one.
Find candidates like President at Profound Medical Corp.New leaders review vendors and budgets in their first months. Get an alert the next time Profound Medical Corp. is in the news or changes leadership.
Get an alert when Profound Medical Corp. changes leadershipTools for this story
Each opens in a new tab, filled in for Profound Medical Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.